Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

KU Leuven and life sciences institute VIB officially unveiled Belgium-based drug development business Augustine Therapeutics today with €4.2m ($4.7m) in seed funding to target neuromuscular disorders such as Charcot–Marie–Tooth (CMT) disease. The money was supplied by VIB and its affiliate V-Bio Ventures venture fund, as well as KU Leuven-backed seed vehicle Gemma Frisius Fund, Flemish government-owned investment firm PMV and life sciences-focused VC firm Advent France Biotechnology. CMT is a hereditary disease characterised by progressive loss of nerve function in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?